Aspirus Regional Cancer Center

Cancer Clinical Trials

This is a current listing of active clinical trials at the Aspirus Regional Cancer Center. From this list you can select a specific cancer that you are interested in (for example, breast or colon cancer) and then review the clinical trials that are active at the Aspirus Regional Cancer Center for that specific disease.

Melenoma - Advanced

Trial Name: A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High dose Interferon a-2b for Resected High-Risk Melanoma.

Protocol ID: ECOG - 1609

Eligibility:

  • Only patients with melanoma of a cutaneous origin or unknown primary are eligible for this study.  Patients with ocular melanoma or melanoma of mucosal origin are not eligible.
  • Age > 18 years.
  • All patients must have disease that is completely surgically resected in order to be eligible.
  • Patients must meet required laboratory values.
  • Patients must not have received any adjuvant treatment (chemotherapy, biotherapy, or limb perfusion) after the resection(s) that make(s) them eligible for this trial.
  • Prior treatment with anti-CTLA4 monoclonal antibodies or prior CTLA-4 inhibitor or agonist or prior CD137 agonist or prior interferon Alfa-2b is not allowed.
  • Patients must not have an active infection requiring current treatment with parenteral antibiotics.
  • Patients who have other current malignancies are not eligible.  Patients with other malignancies are eligible if they have been continuously disease free for > 5 years prior to the time of randomization.  Patients with prior history at any time of any in situ cancer, lobular carcinoma of the breast in situ, cervical cancer in situ, atypical melanocytic hyperplasia or melanoma in situ are eligible.  Patients with prior history of basal or squamous skin cancer are eligible.  Patients who have had multiple primary melanomas are eligible.

Women must not be pregnant or breast-feeding due to the unknown effects of ipilimumab and HDI on conception and the fetus. 

Enrollment: • About 1000 people will take part in this study at several medical centers.

Benefits:

 

Benefits:

Taking part in this study may or may not make your health better.  While doctors hope that ipilimumab will be more useful against cancer compared to the usual treatment, there is no proof of this yet.  We do know that the information from the study will help doctors learn more about ipilimumab and interferon Alfa-2b as a treatment for caner.  This information could help future cancer patients.

Contact:

These clinical trial overviews are intended to provide a brief overview of the clinical trial. To help determine whether the trial is appropriate for you, the major eligibility criteria are listed above. To obtain more information on the eligibility and the treatment plan, please contact our Oncology Clinical Research Coordinator, Beth Knetter at 715-847-2353 or 1-800-283-2881, ext.72353.

Created: Jun 3, 2011

Updated: Jan 20, 2013

« Return to Trials